

*J Pathol* 2016; **238**: 300–310

Published online 13 November 2015 in Wiley Online Library

([wileyonlinelibrary.com](http://wileyonlinelibrary.com)) DOI: 10.1002/path.4641

INVITED REVIEW

# Animal modelling for inherited central vision loss

Corinne Kostic\* and Yvan Arsenijevic\*

Unit of Gene Therapy and Stem Cell Biology, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, University of Lausanne, Switzerland

\*Correspondence to: C Kostic or Y Arsenijevic, Hôpital Ophtalmique Jules-Gonin, Avenue de France 15, 1004 Lausanne, Switzerland.  
E-mail: [Corinne.kostic@fa2.ch](mailto:Corinne.kostic@fa2.ch) or [yvan.arsenijevic@fa2.ch](mailto:yvan.arsenijevic@fa2.ch)

## Abstract

Disease-causing variants of a large number of genes trigger inherited retinal degeneration leading to photoreceptor loss. Because cones are essential for daylight and central vision such as reading, mobility, and face recognition, this review focuses on a variety of animal models for cone diseases. The pertinence of using these models to reveal genotype/phenotype correlations and to evaluate new therapeutic strategies is discussed. Interestingly, several large animal models recapitulate human diseases and can serve as a strong base from which to study the biology of disease and to assess the scale-up of new therapies. Examples of innovative approaches will be presented such as lentiviral-based transgenesis in pigs and adeno-associated virus (AAV)-gene transfer into the monkey eye to investigate the neural circuitry plasticity of the visual system. The models reported herein permit the exploration of common mechanisms that exist between different species and the identification and highlighting of pathways that may be specific to primates, including humans.

© 2015 The Authors. *The Journal of Pathology* published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

**Keywords:** blindness; retinal degeneration; fovea; macula; cones

Received 8 July 2015; Revised 2 September 2015; Accepted 16 September 2015

No conflicts of interest were declared.

## The importance of cones for vision

Human vision is based on three systems of photosensitivity: (1) rod photoreceptors, (2) cone photoreceptors, and (3) melanopsin-expressing retinal ganglion cells. Together, these photosensitive cells cover 12 log of light intensity units [1]. Rod photoreceptor cells are responsible for the detection of stimuli in dim light, whereas cone photoreceptor cells transmit visual information in bright light conditions. Melanopsin-expressing retinal ganglion cells are also sensitive to bright light, and are implicated in non-image-forming visual functions such as circadian synchronization or pupillary light reflexes. Cones also provide colour vision and high visual acuity, allowing precise tasks such as reading or facial recognition. Phototransduction occurs in the long process of photoreceptor cells, termed the outer segment (OS), that is linked to the cell body by the inner segment (IS), which contains mitochondria. Without neglecting the heavy consequences of rod loss for vision (night blindness, for example), loss of the cone system is dramatic in our highly technological world, where reading and visual communication are extremely important for social interactions. Moreover, in patients suffering from rod deficiency, a secondary death of cones is observed which definitely worsens their quality of life. To date, no molecular therapy has been successful in stopping cone degeneration, and

physicians can only encourage patients to adapt to their vision loss or propose diets that might slow the process in certain conditions [2]. Thus, the study of cone degeneration mechanisms and the examination of innovative therapeutic strategies are a major field of research in ophthalmology.

Very good reviews on retinal dystrophies, including cone dystrophies, were recently published and we encourage the reader to refer to these works for an exhaustive documentation [3–5]. The present review focuses mainly on genetically modified models and summarizes the naturally occurring models for pronounced cone dystrophies (Table 1).

## In vitro modelling of cone photoreceptors

The development of induced pluripotent stem cells (iPSCs) has brought new opportunities to dissect *in vitro* the molecular mechanisms of cone degeneration. Fibroblasts or blood cells may be reprogrammed using four key genes (*Oct3/4*, *Sox2*, *Klf4*, and *c-Myc*) to acquire an embryonic stem cell-like stage [6] which is characterized by pluripotency. These cells, or embryonic stem cells, can then be differentiated into cell types of interest such as photoreceptor cells [7–10]. The *in vitro* generation of cones from patients with specific cone disorders could thus provide an accurate model to study

Table 1. Summary of the animal models for cone dystrophies. The table lists the animal models described in the review, compiling the species, the name of the gene that was modified, the method of generation of the model, and the human disease targeted


Model	Species	Gene	Method of generation	Human condition	Reference
<i>pTol2:3.2 gnat2-RETGC-1 E837D R838S</i>	<i>Danio rerio</i>	<i>RETGC-1</i>	Embryo injection and transposase system	CORD6	[27]
<i>rd/rd</i> Rhode Island Red chicken	<i>Gallus gallus domesticus</i>	<i>GC1</i>	Spontaneous mutation	LCA	[35]
<i>Rpe65<sup>R91W/R91W</sup></i>	<i>Mus musculus</i>	<i>Rpe65</i>	ES homologous recombination	LCA	[40]
<i>Rpe65<sup>-/-</sup></i>	<i>Mus musculus</i>	<i>Rpe65</i>	ES homologous recombination	LCA	[42]
<i>Rpe65<sup>d12</sup></i>	<i>Mus musculus</i>	<i>Rpe65</i>	Spontaneous mutation	LCA	[41]
<i>Lrat<sup>-/-</sup></i>	<i>Mus musculus</i>	<i>Lrat</i>	ES homologous recombination	LCA, RP	[128]
<i>Nrl<sup>-/-</sup></i>	<i>Mus musculus</i>	<i>Nrl</i>	ES homologous recombination	ESCS syndrome	[53]
<i>rd7</i>	<i>Mus musculus</i>	<i>Nr2e3</i>	Spontaneous mutation	ESCS syndrome	[55]
<i>Rpe65<sup>-/-</sup>;Nrl<sup>-/-</sup></i>	<i>Mus musculus</i>	<i>Rpe65;Nrl</i>	Breeding of single knockout	Macula region	[63,65]
<i>Rpe65<sup>R91W/R91W</sup>;Nrl<sup>-/-</sup></i>	<i>Mus musculus</i>	<i>Rpe65;Nrl</i>	Breeding of single knockout	Macula region	[66]
<i>Gucy2e<sup>-/-</sup>;Nrl<sup>-/-</sup></i>	<i>Mus musculus</i>	<i>Gucy2e;Nrl</i>	Breeding of single knockout	Macula region	[71]
Sudanian grass rat	<i>Arvicanthis ansorgei</i>		MNU and light-induced toxicity	Macular degeneration	[51,52]
Nile grass rat	<i>Arvicanthis niloticus</i>			Macula region	[49]
Awassi sheep	<i>Ovis orientalis</i>	<i>CGNA3</i>	Spontaneous mutation	ACHM	[72]
Pig <i>TgP347L</i> , Pig- <i>Tg N1Pet</i>	<i>Sus scrofa</i>	<i>RHO</i>	Pronuclear injection and homologous recombination	RP	[79]
Pig <i>TgP23H</i> , line 53-1	<i>Sus scrofa</i> , NIH minipig	<i>RHO</i>	Somatic cell nuclear transfer	RP	[80]
Pig <i>ELOVL4-790e794delAACTT</i>	<i>Sus scrofa</i>	<i>ELOVL4</i>	Pronuclear injection and homologous recombination	STDG3	[91]
Pig <i>ELOVL4-Y270terEYFP</i>	<i>Sus scrofa</i>	<i>ELOVL4</i>	Somatic cell nuclear transfer	STDG3	[91]
Pig <i>GUCY2D-E837D;R838S</i>	<i>Sus scrofa</i>	<i>GUCY2D</i>	Lentiviral-directed transgenesis	CORD6	[93]
<i>cmr1, cmr2, cmr3</i>	<i>Canis lupus</i>	<i>BEST1</i>	Spontaneous mutation	Macular dystrophy	[95]
<i>XLRA1, XLRA2</i>	<i>Canis lupus</i>	<i>RPGR</i>	Spontaneous mutation	XLRP	[96]
<i>crd</i>	<i>Canis lupus</i>	<i>NPHP4</i>	Spontaneous mutation	LCA	[98]
<i>crd</i>	<i>Canis lupus</i>	<i>RPGRIP1</i>	Spontaneous mutation	LCA	[101]
<i>crd2</i>	<i>Canis lupus</i>	<i>NPHP5, IBQ1</i>	Spontaneous mutation	LCA, SLSN	[100]
<i>crd3</i>	<i>Canis lupus</i>	<i>ADAM9</i>	Spontaneous mutation	CORD9	[106]
Achromatopsia Alaskan Malamute	<i>Canis lupus</i>	<i>CNGB3</i>	Spontaneous mutation	ACHM	[110]
Achromatopsia German Shorthaired Pointer	<i>Canis lupus</i>	<i>CNGB3</i>	Spontaneous mutation	ACHM	[110]
Retinal transduced squirrel monkey	<i>Saimiri sciureus</i>	<i>L-OPSIN</i>	Somatic retinal transfer	Trichromacy recovery	[111]

cone imbalance or cone death and to screen therapeutic compounds. Although the creation of retina-like tissue derived from iPSCs allows analysis of photoreceptor generation [11–13], the production of human cones is still poor and the process does not recapitulate the formation of the macula or the subsequent synaptic connecting network. In consequence, the first disadvantage of these *in vitro* models is that so far, no culture system enables study of the mechanisms of human macular degeneration, especially when this loss is due to a deficiency of neighbouring cells such as Müller and retinal pigmented epithelial (RPE) cells. Special effort to adapt cultures of multiple cell types would thus be needed to mimic *in vivo* conditions. Second, in some cone dystrophy cases, the time necessary to obtain cone degeneration might not be perfectly reproducible *in vitro* as the onset varies from shortly after birth (achromatopsia) to 70 years of age (as in some patients affected by the Stargardt diseases, see the review by Roosing *et al* [4]). Third, even if this *in vitro* model could be useful to screen for the potential of specific compounds to rescue cones, it could not fully validate the efficiency of the technological transfer *in vivo* or assess for the global effect induced in the long term.

### Non-mammalian cone-rich models

Retinal research benefits from a wide panel of animal models. Many gene deficiencies implied in visual defects affect only vision which, at least in laboratory conditions or domestic breeding, is not required for survival. Thus, numerous animal models have been described following spontaneous mutations of genes also involved in human retinal disorders [3,14,15]. Most rodents, like most mammals, are dichromatic and have only two types of cones, sensitive to medium (M-cone) and short (S-cone) wavelengths, in contrast to primates and humans, who have three types of cones: short (blue), medium (green), and long (L-, red) wavelengths (Figure 1). Interestingly, birds, reptiles, and fishes are also at least trichromatic or even tetrachromatic, which gives alternatives to researchers for modelling cone disorders.

Among fishes, the model of choice selected for development and physiopathology studies is the zebrafish, thanks to its widely known genetics [16], even though several cone physiological studies have been performed using carp. In addition to carrying three cone types, the zebrafish has a fourth UV-type of cone, as well



**Figure 1.** Schematic representation of cone distribution in the central retina of different species. Both sections of the outer nuclear layer and visualization of the eye fundus were schematically represented to highlight the specific cone distribution of the retina of zebrafish, chick, mouse, sheep, pig, dog and human. Photoreceptor types are arbitrarily coloured to represent the different categories of cones (L, M, S, and double cones) and rods. The wavelength of each photopigment is also indicated. (A) In zebrafish, in addition to S- and UV-cones, a double cone is observed with fusion at the level of the IS of two OSs containing either L- or M-opsin. The four classes of cones are then laid out in a regular mosaic pattern. (B) The chick retina contains five types of cones comprising a double cone (in yellow) as well. The different types of cones are homogeneously arranged in the retina. A particular vascular extension, the pecten (red rectangle), is apposed at the inner part of the retina. (C) The mouse retina is composed of only 3% cones, distributed throughout the retina. A dorso-ventral gradient of cone expression is observed, with S-opsin mainly expressed in the inferior hemisphere and M-opsin in the superior hemisphere. However, both opsins are observed in single cells in the overlapping gradient. (D) The sheep retina includes two types of cones, with higher densities of cones in the central streak and in the dorso-temporal region. S-cones are enriched in this particular peripheral region. Sheep have a tapetum, a membrane reflecting the light in the superior hemisphere (yellow area) except in the dorso-nasal periphery. (E) The pig retina features two types of cones, with densities higher in the central streak. (F) The dog retina is also characterized by two types of cones and a central streak, but recently a fovea-like region was identified with an increased number of cones and a longer OS. Dogs also have a tapetum in the superior hemisphere (yellow area). (G) The human central retina is characterized by a region with exclusively cones named the fovea, containing mainly L- and M-cones. S-cones are distributed in the perifovea region and in the periphery. ONL: outer nuclear layer; OS: outer segment; black circle: optic nerve head; red lines: vessels; S: superior; I: inferior; N: nasal; T: temporal. Source: refs 32, 72, 94, and 112–127; <http://www.cvrl.org/database/text/intros/introdens.htm>



as calyceal processes, which are membrane extensions from the apical side of the IS surrounding the basal part of the OS [17] and are described in primate cones but are absent in mouse cones [18]. Several external factors such as light exposure have been used to induce and study photoreceptor degeneration [19–22]. In addition to screening of mutagenized zebrafish stocks [23,24], gene editing tools offer many possibilities to engineer zebrafish models for specific genes [25]. However, the major limitation of zebrafish models is the capacity of the retina to regenerate, which may affect the parallelism with patients [26]. For example, a dominant mutant allele of the guanylate cyclase 2D (*GUCY2D*) gene under the control of a cone promoter was used to perform transgenesis with a transposase system [27] in order to model the phenotype of cone–rod dystrophy (CORD6) patients [28–30]. In these families, the first symptoms described are decreased visual acuity, followed by loss of colour discrimination during the first decade. In the transgenic *GUCY2D* mutant zebrafish model, no early changes in visual function (optokinetic response) were detected, despite decreased staining of cone and rod markers in both larva and adults. Whether the regenerative properties of the zebrafish retina impaired the progression of the disease remains unknown.

Chickens are an alternative model suitable for cone studies, thanks to the high content of cones in their retinas [31,32]. Moreover, the embryonic stages are easily accessible and the large size of the chick eye during development makes them an appreciated model for development studies [33,34]. No transgenic models for retinal diseases have been engineered but the spontaneous model of *GCI* gene loss of function [35] was used to demonstrate the efficiency of gene replacement using lentiviral vectors [36]. A retinal detachment model was also produced by subretinal injection of saline or hyaluronic acid to study cone survival in this paradigm [37]. However, the organization of the chicken vasculature is different from that in humans as their retina is avascular but with a highly glial and vascular structure called the pecten, which is localized in the vitreous of the eye [38,39]. Thus, the retina's morphology appears different between birds and mammals, as probably is cone physiology.

### Novel perspectives on rodent modelling of cone-rich retina

Mouse and rat animal models of cone dystrophy face a major limitation due to the absence of the highly specialized central region found in the monkey and human retina forming the macula and the fovea (Figure 1). As murine and rat retinas have only 3% of cone-type cells spread within rods, they are more adapted for modelling the peripheral primate retina, where the blue-sensing cones are mainly distributed. For example, in the *Rpe65<sup>R91W</sup>* knock-in mouse model where a mutation encountered in patients was substituted to the murine

wild-type codon [40], S-cones were rapidly affected and degenerated during the first months of life. The cone loss was even more rapid in the case of complete ablation of the gene (*Rpe65<sup>-/-</sup>* or the *Rpe65<sup>rd12</sup>* spontaneous model [41,42]) or in other chromophore-deficient models (*Lrat<sup>-/-</sup>* [43]). This early degeneration of S-cones is consistent with the phenotype of patients with RPE65 p.R91W, who endure early blue cone dysfunction in addition to rod desensitization [44]. Interestingly, Samardzija *et al* demonstrated that in cases of limited levels of chromophore in mice, rods compete with cones for chromophore loading [45]. This observation could explain why the peripheral human blue cones (equivalent to the murine S-cones) might be more affected than foveal cones in these patients deficient in RPE65.

In order to find rodent retinas enriched in cones, some researchers have looked further amongst diurnal animals, which are in general richer in cones than nocturnal ones [46]. Examination of the retinas of *Arvicanthis ansorgei* and *A. niloticus*, the Sudanian and Nile grass rats, respectively, revealed a ten-fold higher number of cones compared with *Mus musculus* [47–49]. As these animals are genetically closer to mouse than the ground squirrel (90% cones) [50], research using them can benefit from many tools developed for mice (antibodies, databases, maintenance, etc). The 30% of cones composing the *A. ansorgei* retina were thus proposed to offer a better model for the human macula. This model was used to demonstrate the separate cone death succeeding rod death in the case of MNU-induced toxicity, as well as the high resistance of cones to stress [51,52]. However, no models for specific gene dysfunctions have been described yet, limiting the studies of *Arvicanthis* retinas to the use of external damaging factors.

In contrast, the deep understanding of the genetics of retinal development in mice created opportunities to generate mouse models deprived of rods and enriched in cone-like cells. The genetic ablation of the *Nrl* transcription factor in the *Nrl<sup>-/-</sup>* mouse impairs rod development and maintains the precursor in the default cone differentiation pathway [53,54]. Similar results were observed in *rd7* mice, where a retrotransposon is inserted in the *Nr2e3* gene, a downstream target of *Nrl*. In the retina of *rd7* mice, hybrid photoreceptors called 'cods', displaying many characteristics of S-cones, are present but no enhanced S-cone system is detected by electroretinogram (ERG) recordings [55–59]. In humans, *NRL* gene variants have been identified in patients suffering from an enhanced S-cone sensitivity syndrome. Studies in the *Nrl<sup>-/-</sup>* mouse have enabled a better understanding of the origin of supranormal photopic activities of patients but have also revealed the phagocytosis defect of *Nrl<sup>-/-</sup>* cone OSs, which seems consistent with imaging reported in patients [60]. Moreover, transient and partial cone degeneration was observed between 1 and 4 months in *Nrl<sup>-/-</sup>* mice, followed by the long-term persistence of remaining cones [61]. The circulating retinal current of the young adult *Nrl<sup>-/-</sup>* retina enriched in cone-like cells is less demanding of oxygen compared with a WT rod-rich retina [61,62]. Hyperoxic conditions

are thus created and are thought to induce a remodelling of the *Nrl*<sup>-/-</sup> retinal architecture with Müller cell activation, RPE atrophy, and loss of vasculature. Consistent with this hypothesis is the work on the *Rpe65*<sup>-/-</sup>;*Nrl*<sup>-/-</sup> double knockout mouse that showed a role for the chromophore in the formation of rosettes in the *Nrl*<sup>-/-</sup> background, because the absence of 11-*cis*-retinal in the *RPE65*<sup>-/-</sup> background allows recovery of a normal layered retina [63–65]. However, these mice have no visual function, due to the absence of a chromophore, and are thus of limited interest. Samardzija *et al* proposed the use of the *Rpe65*<sup>R91W</sup>;*Nrl*<sup>-/-</sup> mouse as an alternative [66], and indeed the persistence of a 10% wt level of RPE65 protein as well as its remaining residual activity allows efficient suppression of the formation of rosettes while maintaining a recordable retinal activity [66]. Retinal markers and functional tests also revealed that the *Rpe65*<sup>R91W</sup> background preserves second- and third-order neurons (horizontal and retinal ganglion cells) that are usually affected secondarily in the *Nrl*<sup>-/-</sup> background. The vasculature was also rescued and this renders the *Rpe65*<sup>R91W</sup>;*Nrl*<sup>-/-</sup> mouse a reliable all-cone retina model with a preserved retinal architecture. In this complex genetic background, cone loss can be studied in acute or slow degeneration processes using MNU administration or specific ablation of phosphodiesterase (PDE) genes [66].

Other gene defects have been examined in this *Nrl*<sup>-/-</sup> cone-only background and highlight the efficiency of cone rescue after gene replacement strategies. For example, Du *et al* [67] demonstrated the efficiency of intra-vitreous injection of the AAV8 (Y447, 733 F) vector to target cones and restore vision in *Cnga3*<sup>-/-</sup>;*Nrl*<sup>-/-</sup> mice. The AAV8 (Y447, 733 F) capsid is a genetically modified capsid 8 protein which can cross the retina from the inner side and reach the outer part of the retina to transduce photoreceptor cells. The authors thus validated a less damaging approach for vector delivery to cones than subretinal injection [67]. Similarly, Boye *et al*, after validation in multiple guanylate cyclase-deficient murine models of Leber congenital amaurosis [68–70], also demonstrated cone rescue in the *Gucy2e*<sup>-/-</sup>;*Nrl*<sup>-/-</sup> model after subretinal injection of AAV8 (Y733)-hGRK1-*Gucy2e* or AAV5-hGRK1-*Gucy2e* vectors [71]. Taken together, these results demonstrate how fundamental research on the development and physiology of the rodent retina has opened new perspectives for disease modelling and therapy development.

### Naturally-occurring cone dystrophy in sheep

The sheep retina, although having no macula, shows two cone-enriched regions: a streak in the central part of the retina and a dorso-temporal small area (Figure 1D). The central region is termed the area centralis and is composed of two cone types [short wavelength (S-cone) and medium/long wavelength cones (M/L-cones)], but

S-cone density is particularly high in the dorso-temporal region. In addition, a tapetum, a layer located behind the retina, covers the dorso-temporal region with an extension towards the nasal area. This tapetum enhances the chance of photon capture by the photoreceptors by reflecting photons back to the retina. A naturally-occurring day blindness was observed in the improved Awassi breed [72] and was associated with a mutation in the gene encoding the  $\alpha$  subunit of the cone photoreceptor cyclic nucleotide-gated (CNGA3) [73]. Lambs showed an almost normal rod function, whereas ERG recorded in photopic conditions (in which the animal is light-adapted and receives stimuli in presence of an illuminated background) revealed a diminished amplitude of cone responses. The pupil light reflex was also impaired in the daytime. The presence of a well-preserved retina during the first months of the disease renders these animals an interesting model for a gene therapy treatment to recover cone function at different time points through the course of disease. Recently, Banin *et al* [74] restored cone function in these animals by AAV2/5 gene transfer.

### Transgenic pigs to study retinal dystrophies

The pig retina also contains an area centralis composed of around 30% cones that express M/L-opsin and S-opsin (Figure 1E). Novel therapeutic approaches can be tested using this model since the pig, similarly to primates and humans, presents a fully developed retina at birth, and benefits from an immune system comparable to the human one. Moreover, the large size of the eye makes it particularly suitable for validating procedures that may be suited to use in humans. Among various strategies, pigs have been used to test retinal prosthesis implants [75], cell transplantation [76,77], and vector serotypes as well as promoter activity for gene therapy developments [78].

#### Pig rod dystrophy models for studying cone degeneration

The first transgenic (Tg) pig to model a retinal dystrophy was generated by pronuclear microinjection to mimic a severe form of retinitis pigmentosa caused by the dominant rhodopsin (*RHO*) gene mutation p.P347L [79]. The 5'-upstream region of the human *RHO* gene served as a promoter for the human mutated allele. This work was then followed by the generation of TgP23H pigs [80] using stable-transfected pig fibroblasts, which then served for nuclear transfer. In this study, the transgene was controlled by the phosphoglycerate kinase promoter and the NIH miniature pig (SLA<sup>C/C</sup> haplotype) was used. Although these mutations affect specifically rod function and survival, these models are also interesting for cone studies as cone death is observed following rod loss. This secondary wave of photoreceptor death is hypothesized to be related to a deficit in a survival factor secreted by rods, the rod-derived cone viability factor

(RdCVF [81]) and in nutrients supplied by the choroid, the main component probably being glucose [82]. Very recent work linked RdCVF and glucose by showing that this factor binds cones on basigin-1, favouring glucose intake [83]. This RdCVF deficit is one explanation for the consequence of rod death on cone survival but does not elucidate the whole mechanism governing cone death during the late phase of retinitis pigmentosa. In this context, the availability of large transgenic animal models of retinal dystrophies such as pigs is a very valuable improvement in studying the process of cone death and developing new therapies to inhibit this process.

In both TgP347L and TgP23H pigs, in which rod function is severely affected, cone activity is also altered and continuously declines during the course of the disease [79,80,84]. The TgP347L pig showed a decline of the retinal responses measured by ERG in photopic conditions at 4 and 87 weeks of age [79]. For the TgP23H pig, the first time point investigated was at 14 days of age in the most severely affected animals, and these showed an absence of the scotopic response (in which animals are dark-adapted and receive stimuli in a dark background in order to reveal rod function) [85]. The cone response had declined at 2 months and had decreased to 50% at 3 months of age [80,85]. The photopic response then remained at approximately 30% of the WT response until 18–24 months. Surprisingly, cone morphology, as evidenced by electron microscopy, was already altered during the retina's development at E10.5 and P3, despite normal recordings in photopic conditions obtained at P3 [86]. These two models clearly reveal that cone degeneration rapidly follows rod loss, indicating that cone protection needs to be performed at an early stage of rod dystrophies.

### Stargardt-like macular dystrophy type 3 in pigs

A juvenile form of macular degeneration termed Stargardt-like macular dystrophy type 3 (STGD3) is associated with mutations in the elongation of the very long-chain fatty acids-4 gene (*ELOVL4* [87]), which codes for an enzyme of the elongase family involved in long-chain fatty acid synthesis [88] and is mainly expressed in rods and cones [87]. The cones in the macula are particularly affected, in comparison to rods, by the g.790\_794delAACTT deletion (resulting in the loss of 51 terminal amino acids); the p.Y270X mutation or the allele bearing a double single nucleotide deletion g.[789delT;794delT] also results in a dominant form of the disease [89,90]. A total of 1226 injections into pig pronuclei were performed with a construct expressing *ELOVL4* g.790\_794delAACTT or a fluorescent protein (EYFP) fused at the C-terminus of the p.Y270X variant (p.Y270terEYFP). Gene expression in both constructs was controlled by the *RHO* Rho4.4 promoter (4.4 kb fragment upstream of the rhodopsin coding sequence, the exact origin not being indicated) [91]. The embryos were conveyed into 22 gilts, from which three transgenic animals were generated. Concerning the p.Y270terEYFP construct, a similar number of

embryos were prepared, but with the nuclear transfer technique, and four pig lines were generated. The expression of the transgene appeared to be preferentially present in the cones (only one row of photoreceptors in the area centralis positive for EYFP in the outer part of the ONL). Nonetheless, the ERG recordings revealed that both rod and cone functions were altered in some animals at 14.5 months. These experiments show that the presence of truncated *ELOVL4* proteins recapitulates different features of the STGD3 disease in pigs as it did in mice [88], thus proposing interesting models to study the pathophysiology of this disease.

### Production of a large cohort of transgenic pigs to study CORD6

CORD6 is the most frequent dominant cone dystrophy form in humans. The p.E837D and p.R838S variants of the *GUCY2D* gene product are associated with disease appearance [29,92]. By using a lentiviral vector encoding the mutated *GUCY2D* cDNA controlled by the cone arrestin promoter and injected in fertilized oocytes, Kostic *et al* [93] generated three cohorts of transgenic pigs. Around 50% of the offspring carried from one to six copies of the transgene. No abnormal behaviour or adverse health issues were observed in the piglets, despite integration of the transgene into the pig genome. A series of mobility tests based on vision were performed at different ages in parallel to optical coherence tomography (OCT) and ERG recordings to evaluate the morphological and physiological integrity of the retina. Interestingly, a wide range of response patterns to all these tests was described within the transgenic group. Although the response variability was high in the transgenic pigs, changes in the behaviour tests were observed in several transgenic animals and a significant alteration of transgenic cone activity was noticed by ERG in comparison to WT littermates. Moreover, histology revealed that all transgenic pig eyes had displaced cone nuclei that localized to the OS region, indicating a degenerative process. The overall results show that the *GUCY2D* gene bearing the two disease-causing variants p.E837D and p.R838S alters cone function and visual performance in photopic conditions, and induces a slow process of cone degeneration.

The variability observed among the transgenic animals is a consequence of the lentiviral transgenesis strategy used and may advantageously model the variability of the phenotypes observed in humans due to the incomplete penetrance of the disease. Moreover, the high percentage of the transgenic animal yield with the lentiviral vector (60% in this work) allows for the design of new experimental approaches to study the effect of dominant mutations.

### Dog models for cone dystrophies

Since 26 dog models of retinal dystrophies have already been characterized and described in a very well



documented review [3], we will discuss here new data as well as dog models of cone dystrophy for which the gene mutation leads directly or predominantly to cone alteration. Like pigs, dogs possess an area centralis enriched in cones. However, detailed characterization of this region revealed that in a very small area, described as fovea-like, there is an elevation in the number of cone rows (from 1 to 3) and a decreased number of rod layers from 8 to 2–3 rows. In parallel, the RGC layer almost triples in this region, forming a dome around 200 µm wide. Moreover, cones and rods featured elongated segments [94]. All of these characteristics suggest that the dog retina contains a small fovea-like structure (Figure 1 F). These features render the dog retina very attractive to study gene mutations affecting mainly cone physiology and survival.

The study of two different dog models of cone dystrophies confirms that this fovea-like area behaves differently from other retinal regions. In Best's disease in humans, the macula is first affected, although the genetic mutation alters RPE function in general. In the *BEST1* dog model [95], the first lesion observed, corresponding to detachment of the retina from the RPE layer, appeared in the fovea-like region [94]. This observation suggests that the dog fovea displays a vulnerability to external environmental stresses similar to that in the macula of affected patients. In the dog model of human X-linked progressive retinal atrophy 2 (*XLPR2*), variants in the *RPGR* gene lead to alteration of the structural cilium connecting the IS to the OS. In humans, mutations in the *RPGR* gene result in a wide range of phenotypes; nonetheless, the macula is often severely affected. Interestingly, in the dog model of *RPGR* alteration [96], the fovea is also the first area affected by the mutation, although the *RPGR* protein is altered in all cones. At 2 weeks of age, the cone number is already lower in the affected dog in comparison to WT but this number remains stable for 22 weeks. After this stable period, both cone and rod numbers decrease in the fovea, along the streak, and centrifugally.

These two examples provide evidence that the dog retina is of great value for studying cone diseases that affect the macula preferentially in humans. Several other naturally-occurring cone diseases have also been identified in dogs for which the identification of this fovea-like region may help to establish the first events appearing during these diseases.

### Cone dystrophies linked to cilium alteration

In standard wirehaired dachshund dogs, a mutation in the *NPHP4* gene, altering its product's ability to bind the *RPGRIP1* cilium protein, was associated with an early-onset cone dystrophy [97,98]. Affected dogs showed an early-onset cone alteration at 5 weeks of age, evidenced by ERG in photopic conditions and using flicker stimulations [99]. In the cone rod dystrophy (*Crd2*) cone dystrophy dog, mutations in another member of this gene family, *NPHP5 (IQCB1)*, correlate with cone and rod abnormal segment formation, and

progressive photoreceptor death [100]. Important variability was observed between dogs during the degenerative process. As expected, the mutation in the *RPGRIP1* gene found in the miniature longhaired dachshunds [101] is also linked to retinal ciliopathy. These dogs suffer from cone dysfunction starting at 7 weeks [102,103], but substantial variations in disease onset and severity have been observed in certain colonies [103,104] and not others [105]. Gene augmentation strategies with AAV2/5 and AAV2/8 have demonstrated the feasibility of re-establishing and maintaining cone function in *RPGRIP1*-deficient dogs for at least 2 years.

Considered together, it is clear that these models recapitulate several retinal diseases observed in humans and enable the study of a network of proteins implicated in the mechanisms of ciliopathy in large animals. These results also reveal the existence of other genetic modifiers which remain to be identified.

### Cone dystrophy and extracellular matrix proteins

Glen of Imaal terrier dogs carry a deletion in the *ADAM9* gene resulting in the absence of exons 15 and 16 in the transcript which alters the protein's function [106]. Longitudinal studies (using different dogs) showed that the retinal activity declines with time, affecting both cone and rod functions. These data are in accordance with the progressive loss of the two photoreceptor populations. This animal model reproduces the major features observed in *CORD9* patients and contrasts with the knockout mice that display subtle morphological changes within the RPE/photoreceptor interactions [107].

### Achromatopsia

In Alaskan Malamute dogs, a cone dystrophy was characterized by an early loss of day vision in bright light and normal vision in dim light [108]. Alteration of day vision was detectable between 8 and 12 weeks, and cone function was absent in young adults, as evidenced by red light stimuli. Rod function remained normal during the dog's lifespan. Electron microscopy analyses revealed that disorganization of the cone lamellar discs was already present in young dogs [109]. The high severity of the phenotype is correlated with total absence of the expression of *CNGB3*, which codes for the cone-specific channel subunit beta-3 [110]. A missense mutation in *CNGB3* was also associated with cone vision loss in German shorthaired pointer dogs. In these models, *CNGB3* loss is causative for the day blindness observed in these dogs, similar to the majority of human achromatic patients [4].

### Creating trichromatic vision in the monkey

In the adult squirrel monkey strain (*Saimiri sciureus*), which has calyceal processes as do humans [18], the

females have trichromatic vision (like humans), with cones expressing M, L, and S-opsins, whereas the males are dichromatic, with absence of the L-opsin. Mancuso *et al* [111] investigated whether the adult brain of a male monkey has enough plasticity to integrate the signal of a new chromophore to generate trichromatic vision, by transferring the L-opsin cDNA via AAV2/5 into male M-cones to extend their spectral domain to catch signals from longer wavelengths. This manipulation allowed the monkey not only to recognize a new subtle colour pattern among a grey background, but also to discriminate a blue-green (wavelength 490 nm) form from a red-violet background (wavelength 499 nm), a task which a non-treated animal failed. These results showed that the adult eye and brain can be reprogrammed for trichromatic vision and that the endogenous neural wiring is sufficient to integrate this new signal to augment environment perception. This new discrimination between 'red' and 'green' may be possible because not all red cones were transduced with the green opsin. The relative level of expression of green versus red opsin could also play a role in this acquired colour discrimination. This astonishing work opens up new perspectives for vision rehabilitation and new treatments via gene transfer not only for achromatopsia.

## Perspectives

Gene transfer has been proved to be efficient for the generation of transgenic animal models of different species. However, the main target for this approach is the study of the effect of genetic variants associated with dominant diseases. With the evolution of the gene editing technologies such as the CRISPR/Cas9 system, transgenesis will certainly be bolstered by models for recessive diseases enlarging the panel of molecular pathways available for research. So far, the different large animal models have mainly been used to make or affine genotype/phenotype correlations. In the future, the availability of several of these models will help to establish the molecular mechanism of diseases and allow us to better comprehend the biological differences between rodents and higher vertebrates, as well as prepare for the scale-up of new therapeutic approaches. In this context, large animals such as pigs, with a high rate of reproduction and less ethical concerns from the public, will have an advantage. The use of large animal models will definitively have an important societal impact for regenerative medicine and drug screening before launching a clinical trial.

## Acknowledgments

We thank Dana Wanner and Alexandre Matet for their precious comments.

## Author contribution statement

CK and YA contributed equally to this review.

## References

- Hood DC, Finkelstein MA. Sensory processes and perception. In *Handbook of Perception and Human Performance*, Boff KR, Kaufman L, Thomas JP (eds). John Wiley: Toronto, 1986; **1**: 5-1–5-66.
- Chew EY, Clemons TE, Sangiovanni JP, *et al*. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. *JAMA Ophthalmol* 2014; **132**: 142–149.
- Petersen-Jones SM, Komaromy AM. Dog models for blinding inherited retinal dystrophies. *Hum Gene Ther Clin Dev* 2015; **26**: 15–26.
- Roosing S, Thiadens AA, Hoyng CB, *et al*. Causes and consequences of inherited cone disorders. *Prog Retin Eye Res* 2014; **42**: 1–26.
- Slijkerman RW, Song F, Astuti GD, *et al*. The pros and cons of vertebrate animal models for functional and therapeutic research on inherited retinal dystrophies. *Prog Retin Eye Res* 2015; **48**: 137–159.
- Takahashi K, Tanabe K, Ohnuki M, *et al*. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* 2007; **131**: 861–872.
- Gonzalez-Cordero A, West EL, Pearson RA, *et al*. Photoreceptor precursors derived from three-dimensional embryonic stem cell cultures integrate and mature within adult degenerate retina. *Nature Biotechnol* 2013; **31**: 741–747.
- Hirami Y, Osakada F, Takahashi K, *et al*. Generation of retinal cells from mouse and human induced pluripotent stem cells. *Neurosci Lett* 2009; **458**: 126–131.
- Jayakody SA, Gonzalez-Cordero A, Ali RR, *et al*. Cellular strategies for retinal repair by photoreceptor replacement. *Prog Retin Eye Res* 2015; **46**: 31–66.
- Osakada F, Ikeda H, Mandai M, *et al*. Toward the generation of rod and cone photoreceptors from mouse, monkey and human embryonic stem cells. *Nature Biotechnol* 2008; **26**: 215–224.
- Decembrini S, Koch U, Radtke F, *et al*. Derivation of traceable and transplantable photoreceptors from mouse embryonic stem cells. *Stem Cell Rep* 2014; **2**: 853–865.
- Eiraku M, Takata N, Ishibashi H, *et al*. Self-organizing optic-cup morphogenesis in three-dimensional culture. *Nature* 2011; **472**: 51–56.
- Nakano T, Ando S, Takata N, *et al*. Self-formation of optic cups and storable stratified neural retina from human ESCs. *Cell Stem Cell* 2012; **10**: 771–785.
- Chang B, Hawes NL, Hurd RE, *et al*. Retinal degeneration mutants in the mouse. *Vision Res* 2002; **42**: 517–525.
- Samardzija M, Grimm C. Mouse models for cone degeneration. *Adv Exp Med Biol* 2014; **801**: 567–573.
- Tachibanaki S, Shimauchi-Matsukawa Y, Arinobu D, *et al*. Molecular mechanisms characterizing cone photoresponses. *Photochem Photobiol* 2007; **83**: 19–26.
- Hodel C, Niklaus S, Heidemann M, *et al*. Myosin VIIA is a marker for the cone accessory outer segment in zebrafish. *Anat Rec* 2014; **297**: 1777–1784.
- Sahly I, Dufour E, Schietroma C, *et al*. Localization of Usher 1 proteins to the photoreceptor calyceal processes, which are absent from mice. *J Cell Biol* 2012; **199**: 381–399.
- Thomas JL, Nelson CM, Luo X, *et al*. Characterization of multiple light damage paradigms reveals regional differences in photoreceptor loss. *Exp Eye Res* 2012; **97**: 105–116.



20. Vihtelic TS, Hyde DR. Light-induced rod and cone cell death and regeneration in the adult albino zebrafish (*Danio rerio*) retina. *J Neurobiol* 2000; **44**: 289–307.
21. Vihtelic TS, Soverly JE, Kassen SC, *et al.* Retinal regional differences in photoreceptor cell death and regeneration in light-lesioned albino zebrafish. *Exp Eye Res* 2006; **82**: 558–575.
22. Weber A, Hochmann S, Cimalla P, *et al.* Characterization of light lesion paradigms and optical coherence tomography as tools to study adult retina regeneration in zebrafish. *PLoS One* 2013; **8**: e80483.
23. Gestri G, Link BA, Neuhauss SC. The visual system of zebrafish and its use to model human ocular diseases. *Dev Neurobiol* 2012; **72**: 302–327.
24. Neuhauss SC, Biehlmaier O, Seeliger MW, *et al.* Genetic disorders of vision revealed by a behavioral screen of 400 essential loci in zebrafish. *J Neurosci* 1999; **19**: 8603–8615.
25. Collery RF, Cederlund ML, Smyth VA, *et al.* Applying transgenic zebrafish technology to study the retina. *Adv Exp Med Biol* 2006; **572**: 201–207.
26. Gemberling M, Bailey TJ, Hyde DR, *et al.* The zebrafish as a model for complex tissue regeneration. *Trends Genet* 2013; **29**: 611–620.
27. Collery RF, Cederlund ML, Kennedy BN. Transgenic zebrafish expressing mutant human RETGC-1 exhibit aberrant cone and rod morphology. *Exp Eye Res* 2013; **108**: 120–128.
28. Downes SM, Payne AM, Kelsell RE, *et al.* Autosomal dominant cone–rod dystrophy with mutations in the guanylate cyclase 2D gene encoding retinal guanylate cyclase-1. *Arch Ophthalmol* 2001; **119**: 1667–1673.
29. Gregory-Evans K, Kelsell RE, Gregory-Evans CY, *et al.* Autosomal dominant cone–rod retinal dystrophy (CORD6) from heterozygous mutation of GUCY2D, which encodes retinal guanylate cyclase. *Ophthalmology* 2000; **107**: 55–61.
30. Xiao X, Guo X, Jia X, *et al.* A recurrent mutation in GUCY2D associated with autosomal dominant cone dystrophy in a Chinese family. *Mol Vis* 2011; **17**: 3271–3278.
31. Bruhn SL, Cepko CL. Development of the pattern of photoreceptors in the chick retina. *J Neurosci* 1996; **16**: 1430–1439.
32. Kram YA, Mantey S, Corbo JC. Avian cone photoreceptors tile the retina as five independent, self-organizing mosaics. *PLoS One* 2010; **5**: e8992.
33. Mey J, Thanos S. Development of the visual system of the chick. I. Cell differentiation and histogenesis. *Brain Res Brain Res Rev* 2000; **32**: 343–379.
34. Vergara MN, Canto-Soler MV. Rediscovering the chick embryo as a model to study retinal development. *Neural Dev* 2012; **7**: 22.
35. Semple-Rowland SL, Lee NR, Van Hooser JP, *et al.* A null mutation in the photoreceptor guanylate cyclase gene causes the retinal degeneration chicken phenotype. *Proc Natl Acad Sci U S A* 1998; **95**: 1271–1276.
36. Verrier JD, Madorsky I, Coggin WE, *et al.* Bicistronic lentiviruses containing a viral 2A cleavage sequence reliably co-express two proteins and restore vision to an animal model of LCA1. *PLoS One* 2011; **6**: e20553.
37. Cebulla CM, Zelinka CP, Scott MA, *et al.* A chick model of retinal detachment: cone rich and novel. *PLoS One* 2012; **7**: e44257.
38. Schuck J, Gerhardt H, Wolburg H. The peripapillary glia of the optic nerve head in the chicken retina. *Anat Rec* 2000; **259**: 263–275.
39. Wolburg H, Liebner S, Reichenbach A, *et al.* The pecten oculi of the chicken: a model system for vascular differentiation and barrier maturation. *Int Rev Cytol* 1999; **187**: 111–159.
40. Samardzija M, von Lintig J, Tanimoto N, *et al.* R91W mutation in Rpe65 leads to milder early-onset retinal dystrophy due to the generation of low levels of 11-*cis*-retinal. *Hum Mol Genet* 2008; **17**: 281–292.
41. Pang JJ, Chang B, Hawes NL, *et al.* Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA). *Mol Vis* 2005; **11**: 152–162.
42. Redmond TM, Yu S, Lee E, *et al.* Rpe65 is necessary for production of 11-*cis*-vitamin A in the retinal visual cycle. *Nature Genet* 1998; **20**: 344–351.
43. Fan J, Rohrer B, Frederick JM, *et al.* Rpe65<sup>-/-</sup> and Lrat<sup>-/-</sup> mice: comparable models of Leber congenital amaurosis. *Invest Ophthalmol Vis Sci* 2008; **49**: 2384–2389.
44. Lorenz B, Poliakov E, Schambeck M, *et al.* A comprehensive clinical and biochemical functional study of a novel RPE65 hypomorphic mutation. *Invest Ophthalmol Vis Sci* 2008; **49**: 5235–5242.
45. Samardzija M, Tanimoto N, Kostic C, *et al.* In conditions of limited chromophore supply rods entrap 11-*cis*-retinal leading to loss of cone function and cell death. *Hum Mol Genet* 2009; **18**: 1266–1275.
46. Peichl L. Diversity of mammalian photoreceptor properties: adaptations to habitat and lifestyle? *Anat Rec A Discov Mol Cell Evol Biol* 2005; **287**: 1001–1012.
47. Bobu C, Craft CM, Masson-Pevet M, *et al.* Photoreceptor organization and rhythmic phagocytosis in the Nile rat *Arvicanthis ansorgei*: a novel diurnal rodent model for the study of cone pathophysiology. *Invest Ophthalmol Vis Sci* 2006; **47**: 3109–3118.
48. Bobu C, Lahmam M, Vuillez P, *et al.* Photoreceptor organisation and phenotypic characterization in retinas of two diurnal rodent species: potential use as experimental animal models for human vision research. *Vision Res* 2008; **48**: 424–432.
49. Gaillard F, Kuny S, Sauve Y. Topographic arrangement of S-cone photoreceptors in the retina of the diurnal Nile grass rat (*Arvicanthis niloticus*). *Invest Ophthalmol Vis Sci* 2009; **50**: 5426–5434.
50. Kryger Z, Galli-Resta L, Jacobs GH, *et al.* The topography of rod and cone photoreceptors in the retina of the ground squirrel. *Vis Neurosci* 1998; **15**: 685–691.
51. Boudard DL, Acar N, Bretillon L, *et al.* Retinas of the diurnal rodent *Arvicanthis ansorgei* are highly resistant to experimentally induced stress and degeneration. *Invest Ophthalmol Vis Sci* 2011; **52**: 8686–8700.
52. Boudard DL, Tanimoto N, Huber G, *et al.* Cone loss is delayed relative to rod loss during induced retinal degeneration in the diurnal cone-rich rodent *Arvicanthis ansorgei*. *Neuroscience* 2010; **169**: 1815–1830.
53. Mears AJ, Kondo M, Swain PK, *et al.* Nrl is required for rod photoreceptor development. *Nature Genet* 2001; **29**: 447–452.
54. Swaroop A, Kim D, Forrest D. Transcriptional regulation of photoreceptor development and homeostasis in the mammalian retina. *Nature Rev Neurosci* 2010; **11**: 563–576.
55. Akhmedov NB, Piriev NI, Chang B, *et al.* A deletion in a photoreceptor-specific nuclear receptor mRNA causes retinal degeneration in the rd7 mouse. *Proc Natl Acad Sci U S A* 2000; **97**: 5551–5556.
56. Chen J, Rattner A, Nathans J. Effects of L1 retrotransposon insertion on transcript processing, localization and accumulation: lessons from the retinal degeneration 7 mouse and implications for the genomic ecology of L1 elements. *Hum Mol Genet* 2006; **15**: 2146–2156.
57. Haider NB, Naggert JK, Nishina PM. Excess cone cell proliferation due to lack of a functional NR2E3 causes retinal dysplasia and degeneration in rd7/rd7 mice. *Hum Mol Genet* 2001; **10**: 1619–1626.
58. Corbo JC, Cepko CL. A hybrid photoreceptor expressing both rod and cone genes in a mouse model of enhanced S-cone syndrome. *PLoS Genet* 2005; **1**: e11.
59. Ueno S, Kondo M, Miyata K, *et al.* Physiological function of S-cone system is not enhanced in rd7 mice. *Exp Eye Res* 2005; **81**: 751–758.

60. Mustafi D, Kevany BM, Genoud C, *et al.* Defective photoreceptor phagocytosis in a mouse model of enhanced S-cone syndrome causes progressive retinal degeneration. *FASEB J* 2011; **25**: 3157–3176.
61. Roger JE, Ranganath K, Zhao L, *et al.* Preservation of cone photoreceptors after a rapid yet transient degeneration and remodeling in cone-only *Nrl*<sup>-/-</sup> mouse retina. *J Neurosci* 2012; **32**: 528–541.
62. Daniele LL, Lillo C, Lyubarsky AL, *et al.* Cone-like morphological, molecular, and electrophysiological features of the photoreceptors of the *Nrl* knockout mouse. *Invest Ophthalmol Vis Sci* 2005; **46**: 2156–2167.
63. Feathers KL, Lyubarsky AL, Khan NW, *et al.* *Nrl*-knockout mice deficient in *Rpe65* fail to synthesize 11-*cis* retinal and cone outer segments. *Invest Ophthalmol Vis Sci* 2008; **49**: 1126–1135.
64. Kunchithapautham K, Coughlin B, Crouch RK, *et al.* Cone outer segment morphology and cone function in the *Rpe65*<sup>-/-</sup> *Nrl*<sup>-/-</sup> mouse retina are amenable to retinoid replacement. *Invest Ophthalmol Vis Sci* 2009; **50**: 4858–4864.
65. Wenzel A, von Lintig J, Oberhauser V, *et al.* RPE65 is essential for the function of cone photoreceptors in *NRL*-deficient mice. *Invest Ophthalmol Vis Sci* 2007; **48**: 534–542.
66. Samardzija M, Caprara C, Heynen SR, *et al.* A mouse model for studying cone photoreceptor pathologies. *Invest Ophthalmol Vis Sci* 2014; **55**: 5304–5313.
67. Du W, Tao Y, Deng WT, *et al.* Vitreal delivery of AAV vectored *Cnga3* restores cone function in *CNGA3*<sup>-/-</sup>/*Nrl*<sup>-/-</sup> mice, an all-cone model of *CNGA3* achromatopsiadagger. *Hum Mol Genet* 2015; **24**: 3699–3707.
68. Boye SE, Boye SL, Pang J, *et al.* Functional and behavioral restoration of vision by gene therapy in the guanylate cyclase-1 (*GC1*) knockout mouse. *PLoS One* 2010; **5**: e11306.
69. Boye SL, Conlon T, Erger K, *et al.* Long-term preservation of cone photoreceptors and restoration of cone function by gene therapy in the guanylate cyclase-1 knockout (*GC1KO*) mouse. *Invest Ophthalmol Vis Sci* 2011; **52**: 7098–7108.
70. Boye SL, Peshenko IV, Huang WC, *et al.* AAV-mediated gene therapy in the guanylate cyclase (*RetGC1/RetGC2*) double knockout mouse model of Leber congenital amaurosis. *Hum Gene Ther* 2013; **24**: 189–202.
71. Boye SL, Peterson JJ, Choudhury S, *et al.* Gene therapy fully restores vision to the all-cone *Nrl*<sup>-/-</sup> *Gucy2e*<sup>-/-</sup> mouse model of Leber congenital amaurosis-1. *Hum Gene Ther* 2015; **26**: 575–592.
72. Shamir MH, Ofri R, Bor A, *et al.* A novel day blindness in sheep: epidemiological, behavioural, electrophysiological and histopathological studies. *Vet J* 2010; **185**: 130–137.
73. Reicher S, Seroussi E, Gootwine E. A mutation in gene *CNGA3* is associated with day blindness in sheep. *Genomics* 2010; **95**: 101–104.
74. Banin E, Gootwine E, Obolensky A, *et al.* Gene augmentation therapy restores retinal function and visual behavior in a sheep model of *CNGA3* achromatopsia. *Mol Ther* 2015; **23**: 1423–1433.
75. Schwahn HN, Gekeler F, Kohler K, *et al.* Studies on the feasibility of a subretinal visual prosthesis: data from Yucatan micropig and rabbit. *Graefes Arch Clin Exp Ophthalmol* 2001; **239**: 961–967.
76. Ghosh F, Engelsberg K, English RV, *et al.* Long-term neuroretinal full-thickness transplants in a large animal model of severe retinitis pigmentosa. *Graefes Arch Clin Exp Ophthalmol* 2007; **245**: 835–846.
77. Klassen H, Kiilgaard JF, Zahir T, *et al.* Progenitor cells from the porcine neural retina express photoreceptor markers after transplantation to the subretinal space of allorecipients. *Stem Cells* 2007; **25**: 1222–1230.
78. Mussolino C, della Corte M, Rossi S, *et al.* AAV-mediated photoreceptor transduction of the pig cone-enriched retina. *Gene Ther* 2011; **18**: 637–645.
79. Petters RM, Alexander CA, Wells KD, *et al.* Genetically engineered large animal model for studying cone photoreceptor survival and degeneration in retinitis pigmentosa. *Nature Biotechnol* 1997; **15**: 965–970.
80. Ross JW, Fernandez de Castro JP, Zhao J, *et al.* Generation of an inbred miniature pig model of retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 2012; **53**: 501–507.
81. Leveillard T, Mohand-Said S, Lorentz O, *et al.* Identification and characterization of rod-derived cone viability factor. *Nature Genet* 2004; **36**: 755–759.
82. Punzo C, Kornacker K, Cepko CL. Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. *Nature Neurosci* 2009; **12**: 44–52.
83. Ait-Ali N, Fridlich R, Millet-Puel G, *et al.* Rod-derived cone viability factor promotes cone survival by stimulating aerobic glycolysis. *Cell* 2015; **161**: 817–832.
84. Sommer JR, Wong F, Petters RM. Phenotypic stability of Pro347Leu rhodopsin transgenic pigs as indicated by photoreceptor cell degeneration. *Transgenic Res* 2011; **20**: 1391–1395.
85. Fernandez de Castro JP, Scott PA, Fransen JW, *et al.* Cone photoreceptors develop normally in the absence of functional rod photoreceptors in a transgenic swine model of retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 2014; **55**: 2460–2468.
86. Scott PA, Fernandez de Castro JP, Kaplan HJ, *et al.* A Pro23His mutation alters prenatal rod photoreceptor morphology in a transgenic swine model of retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 2014; **55**: 2452–2459.
87. Zhang K, Kniazeva M, Han M, *et al.* A 5-bp deletion in *ELOVL4* is associated with two related forms of autosomal dominant macular dystrophy. *Nature Genet* 2001; **27**: 89–93.
88. Agbaga MP, Brush RS, Mandal MN, *et al.* Role of Stargardt-3 macular dystrophy protein (*ELOVL4*) in the biosynthesis of very long chain fatty acids. *Proc Natl Acad Sci U S A* 2008; **105**: 12843–12848.
89. Bernstein PS, Tammur J, Singh N, *et al.* Diverse macular dystrophy phenotype caused by a novel complex mutation in the *ELOVL4* gene. *Invest Ophthalmol Vis Sci* 2001; **42**: 3331–3336.
90. Maugeri A, Meire F, Hoyng CB, *et al.* A novel mutation in the *ELOVL4* gene causes autosomal dominant Stargardt-like macular dystrophy. *Invest Ophthalmol Vis Sci* 2004; **45**: 4263–4267.
91. Sommer JR, Estrada JL, Collins EB, *et al.* Production of *ELOVL4* transgenic pigs: a large animal model for Stargardt-like macular degeneration. *Br J Ophthalmol* 2011; **95**: 1749–1754.
92. Kelsell RE, Gregory-Evans K, Payne AM, *et al.* Mutations in the retinal guanylate cyclase (*RETGC-1*) gene in dominant cone-rod dystrophy. *Hum Mol Genet* 1998; **7**: 1179–1184.
93. Kostic C, Lillo SG, Crippa SV, *et al.* Rapid cohort generation and analysis of disease spectrum of large animal model of cone dystrophy. *PLoS One* 2013; **8**: e71363.
94. Beltran WA, Cideciyan AV, Guziewicz KE, *et al.* Canine retina has a primate fovea-like bouquet of cone photoreceptors which is affected by inherited macular degenerations. *PLoS One* 2014; **9**: e90390.
95. Guziewicz KE, Zangerl B, Lindauer SJ, *et al.* Bestrophin gene mutations cause canine multifocal retinopathy: a novel animal model for Best disease. *Invest Ophthalmol Vis Sci* 2007; **48**: 1959–1967.
96. Beltran WA, Hammond P, Acland GM, *et al.* A frameshift mutation in *RPGR* exon ORF15 causes photoreceptor degeneration and inner retina remodeling in a model of X-linked retinitis pigmentosa. *Invest Ophthalmol Vis Sci* 2006; **47**: 1669–1681.
97. Roepman R, Letteboer SJ, Arts HH, *et al.* Interaction of nephrocystin-4 and *RPGRIP1* is disrupted by

- nephronophthisis or Leber congenital amaurosis-associated mutations. *Proc Natl Acad Sci U S A* 2005; **102**: 18520–18525.
98. Wiik AC, Wade C, Biagi T, *et al.* A deletion in nephronophthisis 4 (*NPHP4*) is associated with recessive cone–rod dystrophy in standard wire-haired dachshund. *Genome Res* 2008; **18**: 1415–1421.
  99. Ropstad EO, Bjerkas E, Narfstrom K. Electroretinographic findings in the Standard Wire Haired Dachshund with inherited early onset cone–rod dystrophy. *Doc Ophthalmol* 2007; **114**: 27–36.
  100. Goldstein O, Mezey JG, Schweitzer PA, *et al.* *IQCB1* and *PDE6B* mutations cause similar early onset retinal degenerations in two closely related terrier dog breeds. *Invest Ophthalmol Vis Sci* 2013; **54**: 7005–7019.
  101. Mellersh CS, Bournsnel ME, Pettitt L, *et al.* Canine *RPGRIP1* mutation establishes cone–rod dystrophy in miniature longhaired dachshunds as a homologue of human Leber congenital amaurosis. *Genomics* 2006; **88**: 293–301.
  102. Busse C, Barnett KC, Mellersh CS, *et al.* Ophthalmic and cone derived electrodiagnostic findings in outbred Miniature Long-haired Dachshunds homozygous for a *RPGRIP1* mutation. *Vet Ophthalmol* 2011; **14**: 146–152.
  103. Turney C, Chong NH, Alexander RA, *et al.* Pathological and electrophysiological features of a canine cone–rod dystrophy in the miniature longhaired dachshund. *Invest Ophthalmol Vis Sci* 2007; **48**: 4240–4249.
  104. Miyadera K, Kato K, Aguirre-Hernandez J, *et al.* Phenotypic variation and genotype–phenotype discordance in canine cone–rod dystrophy with an *RPGRIP1* mutation. *Mol Vis* 2009; **15**: 2287–2305.
  105. Lheriteau E, Petit L, Weber M, *et al.* Successful gene therapy in the *RPGRIP1*-deficient dog: a large model of cone–rod dystrophy. *Mol Ther* 2014; **22**: 265–277.
  106. Goldstein O, Mezey JG, Boyko AR, *et al.* An *ADAM9* mutation in canine cone–rod dystrophy 3 establishes homology with human cone–rod dystrophy 9. *Mol Vis* 2010; **16**: 1549–1569.
  107. Parry DA, Toomes C, Bida L, *et al.* Loss of the metalloprotease *ADAM9* leads to cone-rod dystrophy in humans and retinal degeneration in mice. *Am J Hum Genet* 2009; **84**: 683–691.
  108. Aguirre GD, Rubin LF. The electroretinogram in dogs with inherited cone degeneration. *Invest Ophthalmol* 1975; **14**: 840–847.
  109. Aguirre GD, Rubin LF. Pathology of hemeralopia in the Alaskan malamute dog. *Invest Ophthalmol* 1974; **13**: 231–235.
  110. Sidjanin DJ, Lowe JK, McElwee JL, *et al.* Canine *CNGB3* mutations establish cone degeneration as orthologous to the human achromatopsia locus *ACHM3*. *Hum Mol Genet* 2002; **11**: 1823–1833.
  111. Mancuso K, Hauswirth WW, Li Q, *et al.* Gene therapy for red–green colour blindness in adult primates. *Nature* 2009; **461**: 784–787.
  112. Allison WT, Haimberger TJ, Hawryshyn CW, *et al.* Visual pigment composition in zebrafish: evidence for a rhodopsin–porphyropsin interchange system. *Vis Neurosci* 2004; **21**: 945–952.
  113. Bowmaker JK. Birds see ultraviolet light. *Nature* 1980; **284**: 306.
  114. Bowmaker JK, Dartnall HJ. Visual pigments of rods and cones in a human retina. *J Physiol* 1980; **298**: 501–511.
  115. Curcio CA, Allen KA, Sloan KR, *et al.* Distribution and morphology of human cone photoreceptors stained with anti-blue opsin. *J Comp Neurol* 1991; **312**: 610–624.
  116. Curcio CA, Sloan KR, Kalina RE, *et al.* Human photoreceptor topography. *J Comp Neurol* 1990; **292**: 497–523.
  117. Endeman D, Klaassen LJ, Kamermans M. Action spectra of zebrafish cone photoreceptors. *PLoS One* 2013; **8**: e68540.
  118. Gerke CG Jr, Hao Y, Wong F. Topography of rods and cones in the retina of the domestic pig. *Hong Kong Med J* 1995; **1**: 302–308.
  119. Hendrickson A, Hicks D. Distribution and density of medium- and short-wavelength selective cones in the domestic pig retina. *Exp Eye Res* 2002; **74**: 435–444.
  120. Hunt DM, Carvalho LS, Cowing JA, *et al.* Evolution and spectral tuning of visual pigments in birds and mammals. *Philos Trans R Soc Lond B Biol Sci* 2009; **364**: 2941–2955.
  121. Mowat FM, Petersen-Jones SM, Williamson H, *et al.* Topographical characterization of cone photoreceptors and the area centralis of the canine retina. *Mol Vis* 2008; **14**: 2518–2527.
  122. Okano T, Kojima D, Fukada Y, *et al.* Primary structures of chicken cone visual pigments: vertebrate rhodopsins have evolved out of cone visual pigments. *Proc Natl Acad Sci U S A* 1992; **89**: 5932–5936.
  123. Osorio D, Vorobyev M. Photoreceptor spectral sensitivities in terrestrial animals: adaptations for luminance and colour vision. *Proc Biol Sci* 2005; **272**: 1745–1752.
  124. Jacobs GH, Deegan JF 2nd, Neitz J. Photopigment basis for dichromatic color vision in cows, goats, and sheep. *Vis Neurosci* 1998; **15**: 581–584.
  125. Parsons JT, Smith CR, Zhu J, *et al.* Retinal angiography: noninvasive, real-time bubble assessment from the ocular fundus. *Undersea Hyperb Med* 2009; **36**: 169–181.
  126. Shinozaki A, Hosaka Y, Imagawa T, *et al.* Topography of ganglion cells and photoreceptors in the sheep retina. *J Comp Neurol* 2010; **518**: 2305–2315.
  127. Braekevelt CR. Retinal photoreceptor fine structure in the domestic sheep. *Acta Anat (Basel)* 1983; **116**: 265–275.
  128. Batten ML, Imanishi Y, Maeda T, *et al.* Lecithin-retinol acyltransferase is essential for accumulation of all-*trans*-retinyl esters in the eye and in the liver. *J Biol Chem* 2004; **279**: 10422–10432.